Some support for hypothesis derives from a still unreplicated report of that mutations in the LXRA gene may be presents in some cases of familial progressive MS [267]; these mutations are postulated to decrease innate immune suppression of pro-inflammatory mediators, leading to exaggerated attack on myelin as well as impaired remyelination, accelerating axonal loss and MS progression [267]. Here, NR1H3 is linked to myeloid sarcoma.